BACKGROUND: von Willebrand factor (VWF) variant c.2771G>A; p.R924Q has been described as a benign polymorphism or a possible marker for a null allele and been associated with mild bleeding phenotypes. It was identified in several patients in recent type 1 von Willebrand disease (VWD) studies. OBJECTIVES: To determine whether the p.R924Q allele contributes to reduced VWF levels and type 1 VWD. METHODS: One thousand one hundred and fifteen healthy controls and 148 index cases from the MCMDM-1VWD study were genotyped for c.2771G>A; VWF and FVIII levels were analyzed in ABO blood group stratified individuals and the p.R924Q variant was expressed in 293 EBNA cells. RESULTS: c.2771G>A was present in six index cases, five of whom had a second VWF variant which probably contributed to the phenotype. A common core haplotype identified in families, which included the rare G allele of c.5843-8C>G, was present in the majority of 35 c.2771G>A heterozygous controls. c.2771G>A contributed about 10% variance in VWF and FVIII levels in controls and 35% variance when co-inherited with blood group O. Recombinant p.R924Q VWF had no effect on in vitro expression and heterozygous family members had normal VWF-FVIII binding and normal clearance of VWF and FVIII. CONCLUSIONS: The allele bearing c.2771A leads to reductions in VWF and FVIII levels particularly in combination with blood group O. Its inheritance alone may be insufficient for VWD diagnosis, but it appears to be associated with a further VWF level reduction in individuals with a second VWF mutation and it contributes to population variance in VWF and FVIII levels.
BACKGROUND:von Willebrand factor (VWF) variant c.2771G>A; p.R924Q has been described as a benign polymorphism or a possible marker for a null allele and been associated with mild bleeding phenotypes. It was identified in several patients in recent type 1 von Willebrand disease (VWD) studies. OBJECTIVES: To determine whether the p.R924Q allele contributes to reduced VWF levels and type 1 VWD. METHODS: One thousand one hundred and fifteen healthy controls and 148 index cases from the MCMDM-1VWD study were genotyped for c.2771G>A; VWF and FVIII levels were analyzed in ABO blood group stratified individuals and the p.R924Q variant was expressed in 293 EBNA cells. RESULTS: c.2771G>A was present in six index cases, five of whom had a second VWF variant which probably contributed to the phenotype. A common core haplotype identified in families, which included the rare G allele of c.5843-8C>G, was present in the majority of 35 c.2771G>A heterozygous controls. c.2771G>A contributed about 10% variance in VWF and FVIII levels in controls and 35% variance when co-inherited with blood group O. Recombinant p.R924QVWF had no effect on in vitro expression and heterozygous family members had normal VWF-FVIII binding and normal clearance of VWF and FVIII. CONCLUSIONS: The allele bearing c.2771A leads to reductions in VWF and FVIII levels particularly in combination with blood group O. Its inheritance alone may be insufficient for VWD diagnosis, but it appears to be associated with a further VWF level reduction in individuals with a second VWF mutation and it contributes to population variance in VWF and FVIII levels.
Authors: J Eikenboom; V Van Marion; H Putter; A Goodeve; F Rodeghiero; G Castaman; A B Federici; J Batlle; D Meyer; C Mazurier; J Goudemand; R Schneppenheim; U Budde; J Ingerslev; Z Vorlova; D Habart; L Holmberg; S Lethagen; J Pasi; F Hill; I Peake Journal: J Thromb Haemost Date: 2006-04 Impact factor: 5.824
Authors: A Tosetto; F Rodeghiero; G Castaman; A Goodeve; A B Federici; J Batlle; D Meyer; E Fressinaud; C Mazurier; J Goudemand; J Eikenboom; R Schneppenheim; U Budde; J Ingerslev; Z Vorlova; D Habart; L Holmberg; S Lethagen; J Pasi; F Hill; I Peake Journal: J Thromb Haemost Date: 2006-04 Impact factor: 5.824
Authors: Patricia Casais; Gonzalo A Carballo; Adriana I Woods; Ana C Kempfer; Cristina E Farías; Silvia H Grosso; María A Lazzari Journal: Thromb Haemost Date: 2006-08 Impact factor: 5.249
Authors: Juan Carlos Souto; Laura Almasy; Jose Manuel Soria; Alfonso Buil; William Stone; Mark Lathrop; John Blangero; Jordi Fontcuberta Journal: Thromb Haemost Date: 2003-03 Impact factor: 5.249
Authors: Anthony Cumming; Pamela Grundy; Stephen Keeney; William Lester; Said Enayat; Andrea Guilliatt; Derrick Bowen; John Pasi; David Keeling; Frank Hill; Paula H B Bolton-Maggs; Charles Hay; Peter Collins Journal: Thromb Haemost Date: 2006-11 Impact factor: 5.249
Authors: Junmei Chen; Jesse D Hinckley; Sandra Haberichter; Paula Jacobi; Robert Montgomery; Veronica H Flood; Randall Wong; Gianluca Interlandi; Dominic W Chung; José A López; Jorge Di Paola Journal: Blood Date: 2015-05-27 Impact factor: 22.113
Authors: Luciano Baronciani; Ian Peake; Reinhard Schneppenheim; Anne Goodeve; Minoo Ahmadinejad; Zahra Badiee; Mohammad-Reza Baghaipour; Olga Benitez; Imre Bodó; Ulrich Budde; Andrea Cairo; Giancarlo Castaman; Peyman Eshghi; Jenny Goudemand; Wolf Hassenpflug; Hamid Hoorfar; Mehran Karimi; Bijan Keikhaei; Riitta Lassila; Frank W G Leebeek; Maria Fernanda Lopez Fernandez; Pier Mannuccio Mannucci; Renato Marino; Nikolas Nikšić; Florian Oyen; Cristina Santoro; Andreas Tiede; Gholamreza Toogeh; Alberto Tosetto; Marc Trossaert; Eva M K Zetterberg; Jeroen Eikenboom; Augusto B Federici; Flora Peyvandi Journal: Blood Adv Date: 2021-08-10
Authors: Adriana I Woods; Juvenal Paiva; Ana C Kempfer; Debora M Primrose; Alicia N Blanco; Analía Sanchez-Luceros; María A Lazzari Journal: Res Pract Thromb Haemost Date: 2017-12-20